-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris Therapeutics names Liisa Bayko as CFO

PUBT·07/20/2026 12:02:45
Listen to the news
Kalaris Therapeutics names Liisa Bayko as CFO
  • Kalaris Therapeutics appointed Liisa Bayko as chief financial officer as it advances clinical development of TH103 for neovascular age-related macular degeneration.
  • Bayko previously served as managing director and senior biotechnology analyst at Evercore ISI, covering small- and mid-cap biotech companies.
  • Earlier roles included senior biotechnology analyst at JMP Securities, with prior biopharma equity research positions at several firms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200800PRIMZONEFULLFEED9764199) on July 20, 2026, and is solely responsible for the information contained therein.